New guidelines for the management of migraine in primary care

Current Medical Research and Opinion

Volumn 18, Issue 7, 2002, Pages 414-439

  Dowson, A J ^a   Lipscombe, S ^b   Sender, J ^c   Rees, T ^d   Watson, D ^e  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b Park Crescent New Surgery   (United Kingdom)

^c Merrow Medical Practice   (United Kingdom)

^d Hawthorns Surgery   (United Kingdom)

^e Hamilton Medical Group   (United Kingdom)

Author keywords

Acute therapies; Diagnosis; Guidelines; Management; Migraine; Primary care; Prophylaxis

Indexed keywords

ACETYLSALICYLIC ACID PLUS METOCLOPRAMIDE; ALMOTRIPTAN; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ANTIMIGRAINE AGENT; BARBITURIC ACID DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA PROGRANE; CAFERGOT; CLOTAM RAPID; CODEINE PLUS PARACETAMOL; DOMPERAMOL; DOMPERIDONE PLUS PARACETAMOL; ELETRIPTAN; ERGOTAMINE; ISOMETHEPTENE; ISOMETHEPTENE PLUS PARACETAMOL; METHYSERGIDE; METOPROLOL; METOPROLOL TARTRATE; MIDRID; MIGRALEVE; MIGRAMAX; MIGRIL; NADOLOL; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; PARACETAMOL; PARACETAMOL PLUS METOCLOPRAMIDE; PROPRANOLOL; RIZATRIPTAN; SOLPADEINE; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; SYPROL; TIMOLOL; TIMOLOL MALEATE; TOLFENAMIC ACID; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; ZOLMITRIPTAN;

ARTICLE; BEHAVIOR THERAPY; CONSULTATION; DAILY LIFE ACTIVITY; DRUG EFFICACY; ERGOTISM; HEADACHE; HUMAN; MIGRAINE; MONITORING; PHYSIOTHERAPY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; TREATMENT INDICATION;

ALGORITHMS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MEDICAL HISTORY TAKING; MIGRAINE DISORDERS; PATIENT CARE TEAM; PATIENT EDUCATION; PRIMARY HEALTH CARE; QUESTIONNAIRES; REFERRAL AND CONSULTATION;

EID: 0036453940     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079902125001164     Document Type: Article

References (51)

1. Breslau N, Rasmussen BK. The impact of migraine: Epidemiology, risk factors, and co-morbidities. Neurology 2001;56 (Suppl 1):4-12
2. Stewart WF, Shechter A, Lipton RB. Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration. Neurology 1994;44 (Suppl 4):24-39
3. Osterhaus JT, Townsend RJ, Gandek B et al. Measuring the functional status and well-being of patients with migraine headache. Headache 1994;34:337-43
4. Ferrari MD. The economic burden of migraine to society. Pharmacoeconomics 1998;13:667-76
5. Edmeads J, Láinez JM, Brandes JL et al. Potential of the Migraine Disability Assessment (MIDAS) Questionnaire as a public health initiative and in clinical practice. Neurology 2001;56(Suppl 1):S29-34
6. Silberstein SD, Lipton RB. Chronic daily headache. Curr Opin Neurol 2000;13:277-83
7. Dowson AJ. Analysis of the patients attending a specialist UK headache clinic over a 3-year period. Headache 2002; in press
8. Lipton RB, Goadsby PJ, Sawyer JPC et al. Migraine: Diagnosis and assessment of disability. Rev Contemp Pharmacother 2000;11:63-73
9. Lipton RB, Stewart WF, Diamond S et al. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache 2002;41:646-57
10. Lipton RB, Diamond S, Reed M et al. Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache 2001;41:638-45
11. Steiner TJ, MacGregor EA, Davies PTG. Guidelines for all doctors in the diagnosis and management of migraine and tension-type headache. British Association for the Study of Headache 2000; www.bash.org.uk
12. Dowson AJ, Gruffydd-Jones K, Hackett G et al. Migraine Management Guidelines. London: Synergy Medical Education, 2000
13. Lewis TA, Solomon GD. Advances in migraine management. Cleveland Clin J Med 1995;62:148-55
14. Diener HC, Brune K, Gerber WD et al. Therapy of acute migraine attacks and migraine prophylaxis-guidelines of the German Migraine and Headache Society [in German]. Nervenheilkunde 1997;16:500-10
15. Matchar DB, Young WB, Rosenberg JH et al. Multispecialty consensus on diagnosis and treatment of headache: pharmacological management of acute attacks. Neurology 2000;54: www.aan.com/public/practiceguidelines/03.pdf
16. Lipton RB, Silberstein SD. The role of headache-related disability in migraine management. Neurology 2001;56 (Suppl 1):S35-42
17. Bedell AW, Cady RK, Diamond ML et al. Patient-centered strategies for effective management of migraine. Primary Care Network, 2000
18. Lipton RB. Disability assessment as a basis for stratified care. Cephalalgia 1998;18 (Suppl 22):40-6
19. Lipton RB, Cady RK, Stewart WF et al. Diagnostic lessons from the Spectrum study. Neurology 2002;58 (9 Suppl 6):27-31
20. Cady RK, Lipton RB, Hall C et al. Treatment of mild headache in disabled migraine sufferers: Results of the Spectrum study. Headache 2000;40:792-7
21. Dowson AJ, Cady RK. Rapid Reference to Migraine. Mosby: London, 2002
22. Dowson AJ, Gruffydd-Jones K, Hackett G et al. Migraine: Key Facts. Essential Information from MIPCA. Richmond: Synergy Medical Education 1998
23. Lipton RB, Stewart WF. Managing Your Migraine. A Guide for People with Migraine. 1999. available from www.migraine.org.co.uk and www.migraine-disability.net
24. Wilkinson M, MacGregor A. Understanding Migraine & Other Headaches. Banbury: Family Doctor Publications, 1999
25. Holmes WF, MacGregor EA, Sawyer JPC et al. Information about migraine disability influences physicians' perceptions of illness severity and treatment need. Headache 2001;41:343-50
26. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(Suppl 7):19-28
27. Dowson AJ. Migraine and Other Headaches: Your Questions Answered. Edinburgh: Elsevier, 2003: in press
28. Blau JN, Drummond MF. Migraine and Other Headaches. London: Office of Health Economics, 1991
29. Micieli G. Suffering in silence. In Edmeads J, ed. Migraine: A Brighter Future. Worthing: Cambridge Medical Publications 1993;p1-7
30. Lipton RB, Stewart WF, Cady RK et al. Sumatriptan for the range of headaches in migraine sufferers: Results of the spectrum study. Headache 2000;40:783-91
31. Cady RK, Schreiber CP. Sinus headache or migraine? Considerations in making a differential diagnosis. Neurology 2002;58 (9 Suppl 6):10-4
32. Stewart WF, Lipton RB, Kolodner K et al. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia 1999;19:107-14
33. The Headache Impact Test (HIT). www.amIhealthy.com
34. Kosinski M, Bjorner JB, Dahlof C et al. Development of HIT-6, a paper-based short form for measuring headache impact. Cephalalgia 2001;21:334 (Abstract)
35. Dowson AJ. Assessing the impact of migraine. Curr Med Res Opin 2001;17:298-309
36. Mathew NT, Villareal S, Kailasam J. Improvement in headache related disability in chronic daily headache-treatment outcome assessed by MIDAS. Headache 2000;40:420. Abstract
37. Freitag F, Diamond S, Lyss H et al. MIDAS as a healthcare utilization tool in the challenging patient. Cephalalgia 2000;20:365. Abstract
38. Dowson A, Dahlöf C, Malik F. A Multicentre Study Investigating the Association Between Disability (Using Headache Impact Test HIT-6) and IHS Classification (as Determined by an Expert Panel Diary Review). Manuscript in preparation
39. Ramadan NM, Silberstein SD, Freitag FG et al. Multispecialty consensus on diagnosis and treatment of headache: pharmacological management for prevention of migraine. Neurology 2000;54: www.aan.com/public/practiceguidelines/05.pdf
40. Campbell JK, Penzien DP, Wall EM. Evidenced-based guidelines for migraine headache: Behavioural and physical treatments. Neurology 2000;54: www.aan.com/public/practiceguidelines/04.pdf
41. Hackett G, Kerrigan P, Baxendine M et al. Goals of Migraine Management. Surrey, UK: Synergy Medical Education, 1994
42. Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol 1991;31:295-9
43. Lipton RB, Stewart WF, Stone AM et al. Stratified care vs step care strategies for migraine: Results of the Disability in Strategies of Care (DISC) Study. JAMA 2000;284:2599-605
44. Sheftell FD, Fox AW. Acute migraine treatment outcome measures: A clinician's view. Cephalalgia 2000;20 (Suppl 2):14-24
45. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000;60:1259-87
46. 1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet 2001;358:1668-75
47. Welch KM, Mathew NT, Stone P et al. Tolerability of sumatriptan: Clinical trials and post-marketing experience. Cephalalgia 2000;20:687-95
48. 1B/1D agonists. Headache 2000;40:521-7
49. Tfelt-Hansen P, Saxena PR, Dahlöf C et al. Ergotamine in the acute treatment of migraine: A review and European consensus. Brain 2000;123:9-18
50. Diener HC, Limmroth V. The management of migraine. Rev Contemp Pharmacother 1994;5:271-84
51. Dowson AJ. Case file on chronic or recurrent headache. Doctor 2002; in press